Evoke Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Evoke Pharma wird ein Gewinn- und Umsatzwachstum von 124.7% bzw. 59.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 115.3% pro Jahr wachsen soll.

Wichtige Informationen

124.7%

Wachstumsrate der Gewinne

115.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.7%
Wachstumsrate der Einnahmen	59.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:EVOK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	32	9	N/A	N/A	1
12/31/2025	20	1	N/A	N/A	1
12/31/2024	10	-5	N/A	N/A	1
9/30/2024	9	-6	-5	-5	N/A
6/30/2024	8	-7	-6	-6	N/A
3/31/2024	6	-7	-6	-6	N/A
12/31/2023	5	-8	-5	-5	N/A
9/30/2023	4	-8	-6	-6	N/A
6/30/2023	4	-8	-6	-6	N/A
3/31/2023	3	-8	-7	-7	N/A
12/31/2022	3	-8	-7	-7	N/A
9/30/2022	2	-8	-6	-6	N/A
6/30/2022	2	-8	-11	-11	N/A
3/31/2022	2	-8	-11	-11	N/A
12/31/2021	2	-9	-12	-12	N/A
9/30/2021	1	-9	-12	-12	N/A
6/30/2021	0	-9	-8	-8	N/A
3/31/2021	0	-14	-8	-8	N/A
12/31/2020	0	-13	-7	-7	N/A
9/30/2020	N/A	-12	-6	-6	N/A
6/30/2020	N/A	-12	-5	-5	N/A
3/31/2020	N/A	-7	-5	-5	N/A
12/31/2019	N/A	-7	-6	-6	N/A
9/30/2019	N/A	-7	-6	-6	N/A
6/30/2019	N/A	-7	-6	-6	N/A
3/31/2019	N/A	-8	-6	-6	N/A
12/31/2018	N/A	-8	-7	-7	N/A
9/30/2018	N/A	-6	-8	-8	N/A
6/30/2018	N/A	-10	N/A	-10	N/A
3/31/2018	N/A	-9	N/A	-10	N/A
12/31/2017	N/A	-12	N/A	-9	N/A
9/30/2017	N/A	-13	N/A	-7	N/A
6/30/2017	N/A	-11	N/A	-8	N/A
3/31/2017	N/A	-13	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-10	N/A
6/30/2016	N/A	-12	N/A	-10	N/A
3/31/2016	N/A	-12	N/A	-10	N/A
12/31/2015	N/A	-12	N/A	-10	N/A
9/30/2015	N/A	-12	N/A	-11	N/A
6/30/2015	N/A	-14	N/A	-12	N/A
3/31/2015	N/A	-14	N/A	-12	N/A
12/31/2014	N/A	-13	N/A	-12	N/A
9/30/2014	N/A	-12	N/A	-11	N/A
6/30/2014	N/A	-9	N/A	-7	N/A
3/31/2014	N/A	-5	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EVOK wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: EVOK wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: EVOK wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: EVOKDie Einnahmen des Unternehmens (59.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: EVOKDie Einnahmen des Unternehmens (59.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EVOK in 3 Jahren voraussichtlich hoch sein wird

Evoke Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 12%

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Consensus revenue estimates fall by 17%

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.08 loss, revenue downgraded

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

Recent updates

Consensus revenue estimates fall by 12%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

New major risk - Share price stability

Consensus revenue estimates fall by 17%

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.08 loss, revenue downgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Consensus EPS estimates fall by 13%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 57%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Price target decreased to US$7.00

Consensus revenue estimates increase by 25%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Evoke to get US patent for nasal spray Gimoti

Consensus revenue estimates fall by 19%

Price target decreased to US$63.50

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Price target decreased to US$6.50

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

Consensus EPS estimates fall by 29%

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$9.50

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Price target increased to US$9.50

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?